Press |

Bescheiden effect immunotherapie bij prostaatkanker, conclusie Keynote-199

De Keynote-199 studie startte in 2016 binnen DUOS. Vijf DUOS ziekenhuizen participeerden. In maart 2019 waren de eerste resultaten te zien op een ASCO poster sessie.  Sinds vandaag staat de conclusie online in JCO Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.

CONCLUSION: Pembrolizumab monotherapy shows antitumor activity with an acceptable safety profile in a subset of patients with RECIST-measurable and bone-predominant mCRPC previously treated with docetaxel and targeted endocrine therapy. Observed responses seem to be durable, and OS estimates are encouraging.

Meer op DUOS

© 2019, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in